Valneva(VALN) Prnewswire·2025-03-05 00:44Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Valneva SE and its officers or directors following adverse events reported after vaccination with its chikungunya virus vaccine [1][2]. Group 1: Investigation Details - The investigation is initiated on behalf of investors of Valneva SE, focusing on possible securities fraud or other unlawful business practices [1]. - The U.S. Centers for Disease Control and Prevention (CDC) is investigating five hospitalizations for cardiac or neurologic events in individuals aged 65 and older after receiving Valneva's chikungunya virus vaccine [2]. Group 2: Market Impact - Following the CDC's announcement, Valneva's American Depositary Receipt (ADR) price dropped by 6.75 per ADR on February 28, 2025 [2]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [2].